Skip to main content
. 2022 Feb 23;16:832463. doi: 10.3389/fnins.2022.832463

Table 1.

Mean (standard deviation) of the characteristics of the participants.

Session 1 Session 2 Session 3
Disease duration (years) 8.04 (4.10)
L-Dopa equivalent units (mg∙day−1) 675.21 (277.35)
NFoG-Q (score) 17.72 (5.63) 13.04 (8.01) 16.21 (6.10)
MiniMental (score) 26.63 (2.72) 27.04 (2.94) 26.86 (3.48)
HandY stage (score) 2.91 (0.51) 2.88 (0.51) 2.86 (0.36)
UPDRS-II (score) 8.54 (3.78) 6.93 (3.13) 7.29 (2.64)
UPDRS-III (score) 31.83 (14.99) 27.81 (12.80) 24.43 (11.57)
HADS-A (score) 9.8 (5.26) 9.48 (5.73) 10.86 (6.11)
HADS-D (score) 8.6 (5.19) 8.41 (5.58) 10.21 (6.27)
Mini-BESTest (score) 18.37 (6.86) 22.41 (5.17) 23.29 (4.32)
FES-I (score) 33.94 (11.58) 30.85 (11.13) 28.43 (11.67)
TUG (s) 14.44 (7.29) 11.32 (3.41) 12.76 (8.15)
TUG dual task (s) 18.87 (13.36) 14.83 (10.31) 15.36 (12.13)

MoCA, Montreal Cognitive Assessment; HandY, Hoehn and Yahr; NFoG-Q, New Freezing of Gait Questionnaire; UPDRS-II, motor aspects of experiences of daily living Unified Parkinson's disease rating scale; UPDRS-III, motor score Unified Parkinson's disease rating scale; Mini-BESTest, Mini-Test of Balance Assessment System scale; FES-I, Falls Efficacy Scale International; TUG, Timed Up and Go test.